Association of reactive oxygen species-mediated signal transduction with in vitro apoptosis sensitivity in chronic lymphocytic leukemia B cells

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Palazzo, Adam L ^a   Evensen, Erik ^a   Huang, Ying Wen ^a   Cesano, Alessandra ^a   Nolan, Garry P ^b   Fantl, Wendy J ^a,b  

^a Nodality Inc   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; FLUDARABINE; HYDROGEN PEROXIDE; REACTIVE OXYGEN METABOLITE; DRUG DERIVATIVE; PROTEOME; TUMOR MARKER; VIDARABINE;

ADULT; AGED; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CELL POPULATION; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; OUTCOME ASSESSMENT; PROTEIN PHOSPHORYLATION; PROTEOMICS; SECOND MESSENGER; SIGNAL TRANSDUCTION; SINGLE CELL ANALYSIS; SURFACE PROPERTY; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

ARA;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; B-LYMPHOCYTES; CELL LINE, TUMOR; FEMALE; HUMANS; HYDROGEN PEROXIDE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; PHOSPHORYLATION; PROTEOME; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; SINGLE-CELL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; VIDARABINE;

EID: 80053928938     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024592     Document Type: Article

References (62)

1. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, et al. (2000) Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343: 1910-1916.
2. Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, et al. (1999) Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94: 1840-1847.
3. Chiorazzi N, Ferrarini M, (2011) Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities. Blood 117: 1781-1791.
4. Irish JM, Hovland R, Krutzik PO, Perez OD, Bruserud O, et al. (2004) Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell 118: 217-228.
5. Irish JM, Czerwinski DK, Nolan GP, Levy R, (2006) Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells. Blood 108: 3135-3142.
6. Kotecha N, Flores NJ, Irish JM, Simonds EF, Sakai DS, et al. (2008) Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates. Cancer Cell 14: 335-343.
7. Irish JM, Myklebust JH, Alizadeh AA, Houot R, Sharman JP, et al. (2010) B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression. Proc Natl Acad Sci U S A 107: 12747-12754.
8. Kornblau SM, Minden MD, Rosen DB, Putta S, Cohen A, et al. (2010) Dynamic single-cell network profiles in acute myelogenous leukemia are associated with patient response to standard induction therapy. Clin Cancer Res 16: 3721-3733.
9. Rosen DB, Minden MD, Kornblau SM, Cohen A, Gayko U, et al. (2010) Functional characterization of FLT3 receptor signaling deregulation in acute myeloid leukemia by single cell network profiling (SCNP). PLoS ONE 5: e13543.
10. Rosen DB, Putta S, Covey T, Huang YW, Nolan GP, et al. (2010) Distinct patterns of DNA damage response and apoptosis correlate with Jak/Stat and PI3kinase response profiles in human acute myelogenous leukemia. PLoS ONE 5: e12405.
11. Irish JM, Kotecha N, Nolan GP, (2006) Mapping normal and cancer cell signalling networks: towards single-cell proteomics. Nat Rev Cancer 6: 146-155.
12. Brezski RJ, Monroe JG, (2008) B-Cell Receptor. In: Sigalov AB, editors. Multichain Immune Recognition Receptor Signaling: From Spatiotemporal Organization to Human Disease: Landes Bioscience.
13. Gauld SB, Dal Porto JM, Cambier JC, (2002) B cell antigen receptor signaling: roles in cell development and disease. Science 296: 1641-1642.
14. Reth M, (2002) Hydrogen peroxide as second messenger in lymphocyte activation. Nat Immunol 3: 1129-1134.
15. Singh DK, Kumar D, Siddiqui Z, Basu SK, Kumar V, et al. (2005) The strength of receptor signaling is centrally controlled through a cooperative loop between Ca2+and an oxidant signal. Cell 121: 281-293.
16. Irish JM, Czerwinski DK, Nolan GP, Levy R, (2006) Kinetics of B cell receptor signaling in human B cell subsets mapped by phosphospecific flow cytometry. J Immunol 177: 1581-1589.
17. Monroe JG, (2006) ITAM-mediated tonic signalling through pre-BCR and BCR complexes. Nat Rev Immunol 6: 283-294.
18. Fuentes-Panana EM, Bannish G, Karnell FG, Treml JF, Monroe JG, (2006) Analysis of the individual contributions of Igalpha (CD79a)- and Igbeta (CD79b)-mediated tonic signaling for bone marrow B cell development and peripheral B cell maturation. J Immunol 177: 7913-7922.
19. Kraus M, Alimzhanov MB, Rajewsky N, Rajewsky K, (2004) Survival of resting mature B lymphocytes depends on BCR signaling via the Igalpha/beta heterodimer. Cell 117: 787-800.
20. Kraus M, Pao LI, Reichlin A, Hu Y, Canono B, et al. (2001) Interference with immunoglobulin (Ig)alpha immunoreceptor tyrosine-based activation motif (ITAM) phosphorylation modulates or blocks B cell development, depending on the availability of an Igbeta cytoplasmic tail. J Exp Med 194: 455-469.
21. Wienands J, Larbolette O, Reth M, (1996) Evidence for a preformed transducer complex organized by the B cell antigen receptor. Proc Natl Acad Sci U S A 93: 7865-7870.
22. Rolli V, Gallwitz M, Wossning T, Flemming A, Schamel WW, et al. (2002) Amplification of B cell antigen receptor signaling by a Syk/ITAM positive feedback loop. Mol Cell 10: 1057-1069.
23. Smith SH, Reth M, (2004) Perspectives on the nature of BCR-mediated survival signals. Mol Cell 14: 696-697.
24. Ghia P, Chiorazzi N, Stamatopoulos K, (2008) Microenvironmental influences in chronic lymphocytic leukaemia: the role of antigen stimulation. J Intern Med 264: 549-562.
25. Chen L, Huynh L, Apgar J, Tang L, Rassenti L, et al. (2008) ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemia. Blood 111: 2685-2692.
26. Gobessi S, Laurenti L, Longo PG, Carsetti L, Berno V, et al. (2009) Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells. Leukemia 23: 686-697.
27. Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, et al. (2010) Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 115: 2578-2585.
28. Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, et al. (2010) Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 463: 88-92.
29. Gobessi S, Laurenti L, Longo PG, Sica S, Leone G, et al. (2007) ZAP-70 enhances B-cell-receptor signaling despite absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B cells. Blood 109: 2032-2039.
30. Kolb JP, Kern C, Quiney C, Roman V, Billard C, (2003) Re-establishment of a normal apoptotic process as a therapeutic approach in B-CLL. Curr Drug Targets Cardiovasc Haematol Disord 3: 261-286.
31. Hanahan D, Weinberg RA, (2000) The hallmarks of cancer. Cell 100: 57-70.
32. Rassenti LZ, Huynh L, Toy TL, Chen L, Keating MJ, et al. (2004) ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 351: 893-901.
33. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, et al. (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111: 5446-5456.
34. Motiwala T, Majumder S, Kutay H, Smith DS, Neuberg DS, et al. (2007) Methylation and silencing of protein tyrosine phosphatase receptor type O in chronic lymphocytic leukemia. Clin Cancer Res 13: 3174-3181.
35. Gandhi V, Plunkett W, (2002) Cellular and clinical pharmacology of fludarabine. Clin Pharmacokinet 41: 93-103.
36. Krutzik PO, Nolan GP, (2003) Intracellular phospho-protein staining techniques for flow cytometry: monitoring single cell signaling events. Cytometry A 55: 61-70.
37. Hewamana S, Alghazal S, Lin TT, Clement M, Jenkins C, et al. (2008) The NF-kappaB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target. Blood 111: 4681-4689.
38. Hertlein E, Byrd JC, (2008) CLL and activated NF-kappaB: living partnership. Blood 111: 4427.
39. Ghia P, Guida G, Stella S, Gottardi D, Geuna M, et al. (2003) The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. Blood 101: 1262-1269.
40. Sattler M, Winkler T, Verma S, Byrne CH, Shrikhande G, et al. (1999) Hematopoietic growth factors signal through the formation of reactive oxygen species. Blood 93: 2928-2935.
41. Kwon J, Lee SR, Yang KS, Ahn Y, Kim YJ, et al. (2004) Reversible oxidation and inactivation of the tumor suppressor PTEN in cells stimulated with peptide growth factors. Proc Natl Acad Sci U S A 101: 16419-16424.
42. Antoni L, Sodha N, Collins I, Garrett MD, (2007) CHK2 kinase: cancer susceptibility and cancer therapy- two sides of the same coin? Nat Rev Cancer 7: 925-936.
43. Jumaa H, Hendriks RW, Reth M, (2005) B cell signaling and tumorigenesis. Annu Rev Immunol 23: 415-445.
44. Hanley JA, McNeil BJ, (1982) The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143: 29-36.
45. Kay NE, O'Brien SM, Pettitt AR, Stilgenbauer S, (2007) The role of prognostic factors in assessing 'high-risk' subgroups of patients with chronic lymphocytic leukemia. Leukemia 21: 1885-1891.
46. Hamblin TJ, (2007) Prognostic markers in chronic lymphocytic leukaemia. Best Pract Res Clin Haematol 20: 455-468.
47. Tam CS, Shanafelt TD, Wierda WG, Abruzzo LV, Van Dyke DL, et al. (2009) De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience. Blood 114: 957-964.
48. Dohner H, Fischer K, Bentz M, Hansen K, Benner A, et al. (1995) p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 85: 1580-1589.
49. Rhee SG, (2006) Cell signaling. H2O2, a necessary evil for cell signaling. Science 312: 1882-1883.
50. Rao GN, (1997) Protein tyrosine kinase activity is required for oxidant-induced extracellular signal-regulated protein kinase activation and c-fos and c-jun expression. Cell Signal 9: 181-187.
51. Sundaresan M, Yu ZX, Ferrans VJ, Irani K, Finkel T, (1995) Requirement for generation of H2O2 for platelet-derived growth factor signal transduction. Science 270: 296-299.
52. Tonks NK, (2005) Redox redux: revisiting PTPs and the control of cell signaling. Cell 121: 667-670.
53. Contri A, Brunati AM, Trentin L, Cabrelle A, Miorin M, et al. (2005) Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. J Clin Invest 115: 369-378.
54. Buchner M, Fuchs S, Prinz G, Pfeifer D, Bartholome K, et al. (2009) Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia. Cancer Res 69: 5424-5432.
55. Kaplan D, Meyerson HJ, Li X, Drasny C, Liu F, et al. (2010) Correlation between ZAP-70, phospho-ZAP-70, and phospho-Syk expression in leukemic cells from patients with CLL. Cytometry Part B, Clinical cytometry 78: 115-122.
56. Chen L, Juszczynski P, Takeyama K, Aguiar RC, Shipp MA, (2006) Protein tyrosine phosphatase receptor-type O truncated (PTPROt) regulates SYK phosphorylation, proximal B-cell-receptor signaling, and cellular proliferation. Blood 108: 3428-3433.
57. Kato Y, Iwama A, Tadokoro Y, Shimoda K, Minoguchi M, et al. (2005) Selective activation of STAT5 unveils its role in stem cell self-renewal in normal and leukemic hematopoiesis. J Exp Med 202: 169-179.
58. Han L, Wierenga AT, Rozenveld-Geugien M, van de Lande K, Vellenga E, et al. (2009) Single-cell STAT5 signal transduction profiling in normal and leukemic stem and progenitor cell populations reveals highly distinct cytokine responses. PLoS ONE 4: e7989.
59. Xiao W, Hong H, Kawakami Y, Kato Y, Wu D, et al. (2009) Tumor suppression by phospholipase C-beta3 via SHP-1-mediated dephosphorylation of Stat5. Cancer Cell 16: 161-171.
60. Du J, (2002) Combined Algorithms for Fitting Finite Mixture Distributions. McMaster University.
61. Efroni S, Schaefer CF, Buetow KH, (2007) Identification of key processes underlying cancer phenotypes using biologic pathway analysis. PLoS ONE 2: e425.
62. Rassenti LZ, Jain S, Keating MJ, Wierda WG, Grever MR, et al. (2008) Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood 112: 1923-1930.